Allergen Biocube Study Evaluating Efficacy and Safety of Nasapaque Nasal Solution in Adult Subjects With Allergic Rhinitis

A Single-Center, Double-Masked, Randomized, Placebo-Controlled, Parallel-Group Allergen BioCube Study Evaluating the Efficacy and Safety of Nasapaque Nasal Solution in a Population of Adult Subjects With Seasonal Allergic Rhinitis

Status

Completed

Phases

Phase 1Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02377895

Enrollment

Registered

2015-03-04

Start date

2015-03-31

Completion date

2015-07-31

Last updated

2017-01-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Seasonal Allergic Rhinitis

Brief summary

Single-center, double-masked, randomized, placebo-controlled, parallel-group, efficacy and safety study using the Allergen BioCube (ABC).

Interventions

DRUGNasapaque Nasal Solution

DRUGPlacebo Saline Nasal Solution

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

Key Inclusion Criteria: * Must be 18 years of age and provide written informed consent and sign the HIPAA form * Must have history of allergic rhinitis * Must have positive response to Allergen BioCube Key

Exclusion criteria

* Must not have a significant illness such as moderate to severe allergic asthmatic reactions * Must not have compromised lung function * Must not use any disallowed medications * Must not have been in an investigational study in the last 30 days

Design outcomes

Primary

Measure	Time frame
TNSS Total Nasal Symptom Score	Day 1 and Day 8

Secondary

Measure	Time frame
Nasal Inspiratory Flow	Day 1 and Day 8
Nasal Inflammation Score	Day 1 and Day 8

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 21, 2026